Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Zhongzhi Pharmaceutical Holdings (HKSE:03737) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Zhongzhi Pharmaceutical Holdings's EV-to-EBIT for today is
Zhongzhi Pharmaceutical Holdings's current Enterprise Value is HK$666 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhongzhi Pharmaceutical Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$27 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Zhongzhi Pharmaceutical Holdings's EV-to-EBITDA for today is:
Zhongzhi Pharmaceutical Holdings's current Enterprise Value is HK$666 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhongzhi Pharmaceutical Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$140 Mil.
Zhongzhi Pharmaceutical Holdings's current Enterprise Value is HK$666 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhongzhi Pharmaceutical Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,909 Mil.
Zhongzhi Pharmaceutical Holdings's current Enterprise Value is HK$666 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhongzhi Pharmaceutical Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$197 Mil.
Zhongzhi Pharmaceutical Holdings's current Enterprise Value is HK$666 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Zhongzhi Pharmaceutical Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$158 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongzhi Pharmaceutical Holdings Enterprise Value Related Terms
Zhongzhi Pharmaceutical Holdings Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongzhi Pharmaceutical Holdings Enterprise Value Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Zhongzhi Pharmaceutical Holdings's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhongzhi Pharmaceutical Holdings Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhongzhi Pharmaceutical Holdings's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Zhongzhi Pharmaceutical Holdings's Enterprise Value falls into.
Zhongzhi Pharmaceutical Holdings Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhongzhi Pharmaceutical Holdings (HKSE:03737) has a Enterprise Value of HK$666 Mil as of Sep. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Zhongzhi Pharmaceutical Holdings and its competitors.
Is Zhongzhi Pharmaceutical Holdings' Enterprise Value too high?
Zhongzhi Pharmaceutical Holdings' current Enterprise Value is HK$666 Mil. Overall, Zhongzhi Pharmaceutical Holdings has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhongzhi Pharmaceutical Holdings' Enterprise Value compare to ZTS?
Zhongzhi Pharmaceutical Holdings' Enterprise Value of HK$666 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Zhongzhi Pharmaceutical Holdings and its competitors. Zhongzhi Pharmaceutical Holdings's current Enterprise Value is HK$666 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhongzhi Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zhongzhi Pharmaceutical Holdings (HKSE:03737) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.89, compared to a current price of HK$0.71 — trading 20.2% below its estimated fair value. The current Enterprise Value is HK$666 Mil. Zhongzhi Pharmaceutical Holdings' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Zhongzhi Pharmaceutical Holdings (HKSE:03737), the current Enterprise Value is HK$666 Mil as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhongzhi Pharmaceutical Holdings (HKSE:03737) Overvalued in 2026?
Based on GuruFocus' analysis, Zhongzhi Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of HK$0.71 is trading 20.2% below its estimated GF Value™ of HK$0.89.
GuruFocus considers Zhongzhi Pharmaceutical Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:03737:
Enterprise Value: HK$666 Mil
GF Value™: HK$0.89 vs. price of HK$0.71 (20.2% below fair value)
No single metric tells the full story. See the HKSE:03737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhongzhi Pharmaceutical Holdings Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceutical products in the PRC. The Group is a large industrial and trading enterprise group featuring researching, producing, and selling traditional Chinese medicine preparations, prepared slices of Chinese crude drugs, and foods. Its products include Shenqi Koufuye, Yinhuang Jiaonang, Yinhuang Keli, and others. Its segments are the pharmaceutical manufacturing segment, which generates maximum revenue, is engaged in the research and development, manufacturing, and sale of Chinese patent medicines and decoction pieces consisting of traditional decoction pieces and modern decoction pieces, and the operation of the chain pharmacies segment.
47GF Score
Get the complete analysis for HKSE:03737
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03737 has been successfully added to your 
